13-5　ⓔ文献

  1. Joseph CG, Darrah E, et al: Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science, 2014; 343: 152–157.

  2. Feghali-Bostwick C, Medsger TA Jr, et al: Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum, 2003; 48: 1956–1963.

  3. Kuwana M, Shirai Y, et al: Elevated serum Krebs von den Lungen–6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol, 2016; 43: 1825–1831.

  4. Weatherald J, Montani D, et al: Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev, 2019; 28: pii: 190023.

  5. Kuwana M: Circulating anti–nuclear antibodies in systemic sclerosis: Utility in diagnosis and disease subsetting. J Nippon Med Sch, 2017; 84: 56–63.

  6. van den Hoogan F, Khanna D, et al: 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum, 2013; 65: 2737–2747.

  7. Minier T, Guiducci S, et al: Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis, 2014; 73: 2087–2093.

  8. Tyndall AJ, Bannert B, et al: Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis, 2010; 69: 1809–1815.

  9. Herrick AL: Controversies on the use of steroids in systemic sclerosis. J Scleroderma Relet Disord, 2017; 2: 84–91.

  10. Tashkin DP, Elashoff R, et al: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med, 2006; 354: 2655–2666.

  11. Hoyles RK, Ellis RW, et al: A multicenter, prospective, randomized, double–blind, placebo–controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum, 2006; 54: 3962–3670.

  12. Tashkin DP, Roth MD, et al: Mycophenolate mofetil versus oral cyclophosphamide in scleroderma–related interstitial lung disease (SLS II): a randomised controlled, double–blind, parallel group trial. Lancet Respir Med, 2016; 4: 708–719.

  13. Volkmann ER, Tashkin DP, et al: Mycophenolate mofetil versus placebo for systemic sclerosis–related interstitial lung disease: An analysis of scleroderma lung studies I and II. Arthritis Rheumatol, 2017; 69: 1451–1460.

  14. Sircar G, Goswami RP, et al: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford), 2018; 57: 2106–2113.

  15. Khanna D, Spino C, et al: Abatacept in early diffuse cutaneous systemic sclerosis: Results of a phase II investigator–initiated, multicenter, double–blind, randomized, placebo–controlled trial. Arthritis Rheumatol, 2020; 72: 125–136.

  16. Khanna D, Denton CP, et al: Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet, 2016; 387: 2630–2640.

  17. Distler O, Highland KB, et al: Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med, 2019; 380: 2518–2528.

  18. van Laar JM, Farge D, et al: Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA, 2014; 311: 2490–2498.

  19. Sullivan KM, Goldmuntz EA, et al: Myeloablative autologous stem–cell transplantation for severe scleroderma. N Engl J Med, 2018; 378: 35–47.

  20. Coghlan JG, Galiè N, et al: Initial combination therapy with ambrisentan and tadalafil in connective tissue disease–associated pulmonary arterial hypertension (CTD–PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis, 2017; 76: 1219–1227.

  21. Matucci–Cerinic M, Denton CP, et al: Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS–2 randomised, double-blind, placebo–controlled trial. Ann Rheum Dis, 2011; 70: 32–38.